EP300 and neoplasm: We further demonstrate that the SIRT3 tumor suppressor interacts with and deacetylates Skp2 (Figure 2), suggesting that targeting Skp2 or the p300/SIRT3 axis could be a novel approach for the treatment of human cancers, especially those with up-regulation of Skp2.